neuraxis dissemination unless there was evidence of ventricular or subarachnoid obstruction. Gross total resection of the primary lesion was attempted when tumor size and location permitted this approach; in other cases surgery was limited to biopsy and/or partial resection. No attempt was made to obtain biopsy material from sites of metastatic disease. In all cases, tumor histology was reviewed by one of the authors (J.J.J.) to confirm the original diagnosis of low-grade neoplasms and the specific tumor type (defined as astrocytoma or juvenile pilocytic astrocytoma). 7 Following biopsy or resection, patients with disseminated disease were treated with chemotherapy and/or radiation therapy. Chemotherapy consisted of cisplatin or carboplatin, alone or in combination with vincristine or etoposide. Craniospinal irradiation to total doses ranging from 35.2 to 38.2 Gy (conventional fractionation) and from 40.0 to 48.4 Gy (hyperfractionation) was given, with a boost to the primary tumor.
Neuroimaging studies were repeated at regular intervals. For patients with measurable primary tumors after surgery, treatment response was determined by calculating changes in the cross-sectional diameter of the primary tumor. Response to radiation therapy was evaluated 8 weeks after treatment was completed; chemotherapy responses were evaluated at regular intervals during treatment and at the termination of chemotherapy.
Responses at the primary site were categorized as follows: complete response, resolution of all tumor on MR images or CT scans; partial response, a 50% or greater decrease in the tumor size; stable disease, less than 50% decrease or less than 25% increase in tumor size; and progressive disease, a 25% or greater increase in primary tumor size. Measurable metastases were categorized similarly. For disseminated disease present only as a thin coating of the underlying brain or spinal cord, disease response was described as "improved," "no change," or "progressive disease" with no attempt at quantitation.
Results
Of 150 patients with a confirmed diagnosis of low-A. Gajjar, et al. grade astrocytoma, eight (5.3%) had neuroimaging evidence of neuraxis dissemination at initial diagnosis. These five male and three female patients ranged in age from 5 months to 20 years (median age 8 years). The primary tumor was located in the hypothalamus in four cases, the temporal lobe in one, the spinal cord in two, and the pons in one. Five tumors were classified as astrocytoma, and three as juvenile pilocytic astrocytoma. The imaging modalities used to define the extent of disease are outlined in Table 1 , along with the patients' clinical characteristics and treatment histories.
All four patients with hypothalamic tumors were found to have tumor deposits lining the walls of the ventricles and in the subarachnoid space overlying the cerebellum and spinal cord; one child also had metastatic disease overlying the cerebral hemispheres. Figures 1 and 2 present contrast-enhanced MR images demonstrating disease dissemination intracranially and over the spinal cord. Figure 1 shows diffuse CSF enhancement following gadolinium contrast infusion; this is best revealed by the subtraction technique ( Fig. 3) and is a sign of leptomeningeal disease. 5, 18 Despite the extensive spinal subarachnoid metastases shown by imaging studies in each of these four cases, only one child (Case 2, Table 1 ) had symptoms of leptomeningeal disease, with diminished spinal flexion. The CSF cytology was negative in the two patients for whom these studies were available. Following biopsy of the primary tumors, three of these patients were treated with platinum-based chemotherapy. One patient is alive with stable disease 3 months after the completion of scheduled chemotherapy. The second patient continues on chemotherapy with stable disease, whereas the third patient had progressive disease at the primary and metastatic sites 2 months after beginning chemotherapy. He was subsequently treated with radiation therapy and is alive with stable disease 4 months postirradiation. The fourth patient was initially treated with craniospinal radiation alone and had markedly progressive symptomatic disease at his 8-week evaluation. He is currently being followed with progressive disease after showing a transient response to Topotecan in a phase I trial.
The two patients with spinal cord tumors and one with a focal pontine tumor also had extensive leptomeningeal metastases coating the spine, cerebellum, cerebral convexities, and basal cisterns in various combinations. course of cisplatin and etoposide followed by scheduled irradiation and is alive with stable disease 80 months after completing therapy. In the two other cases, biopsy was followed by primary craniospinal irradiation. Disease progression was documented at metastatic sites within 16 weeks after treatment in both cases. One of these children had disease stabilization on phase I chemotherapy. Toxicity necessitated discontinuation of chemotherapy, after which the disease progressed. This patient is currently surviving with progressive disease. The other died of rapidly progressive disease.
Only one patient had a primary hemispheric tumor, which was located in the medial left temporal lobe. Local subarachnoid tumor studding and a distant focus of tumor in the ipsilateral subfrontal region were noted at diagnosis. She was treated initially with partial resection of the primary tumor. Her disease recurred locally 33 months later and was treated with craniospinal radiation. She is alive with stable disease 72 months after completing radiation therapy (105 months after diagnosis).
Overall, seven of the eight patients are alive a median of 15 months (range 6 to 105 months) postdiagnosis. Two patients have had stable disease since completing primary chemotherapy, one had progressive disease during chemotherapy that stabilized following radiation therapy, and one remains on chemotherapy with no evidence of progression. Three children had progressive disease after primary radiation therapy. Two of the latter patients are alive with progressive disease following transient response to phase I chemotherapy; the third died of progressive disease soon after completing radiotherapy. The last patient was initially treated with surgery alone; she received radiation therapy at the time of disease progression and presently survives with stable disease.
Discussion
Neuraxis dissemination of low-grade astrocytomas is an uncommon occurrence. Using modern imaging techniques, we identified neuraxis dissemination at the time of diagnosis in 5% of a large series of consecutively accrued patients with low-grade astrocytoma. In contrast to the present series, most reports have described neuraxis dissemination concurrent with or following recurrence at the primary site. Investigators at the Children's Hospital of Philadelphia found neuraxis dissemination in 6 (3.7%) of 162 patients with low-grade astrocytoma, only one of whom was newly diagnosed. 2 Another group reported disseminated disease in 18% of children and adults with hypothalamic juvenile pilocytic astrocytomas at the time of disease progression, but none had apparent dissemination at diagnosis. 11 Autopsy studies suggest that dissemination of tumor cells via the CSF pathways is probably the primary mechanism of metastases within the CNS. 20 Spread via the ventricular CSF was the most likely mechanism of tumor dissemination in our four patients with hypothalamic primary sites. These tumors arise as discrete neoplasms in the floor of the third ventricle, impinging on the optic and infundibular recesses. As they grow, they may breach the ependymal epithelium and shed tumor cells into the third ventricular cavity; normal CSF flow would then carry tumor cells through the aqueduct of Sylvius, the fourth ventricle, and eventually through the foramina of Magendie and Luschka to the rest of the intracranial and spinal subarachnoid space. Viable tumor cells that penetrate the ependymal lining of the ventricle can become attached to the ependyma or leptomeninges at distant sites, proliferating to form metastatic masses. Obstructive hydrocephalus is thought to favor ependymal implantation. 20 In the absence of hydrocephalus, tumor cells do not appear to attach easily to ciliated ependymal surfaces and subarachnoid metastases may be more likely.
A different pattern of spread was seen in the three patients with tumors of the brainstem or spinal cord, whose disease disseminated only to the spinal and cerebral subarachnoid spaces. This pattern suggests direct shedding of tumor into the subarachnoid space and transport via CSF to distant sites within the neuraxis. The absence of ventricular metastases in these cases suggests the inability of tumor cells to move and implant against the direction of normal CSF flow.
The one hemispheric tumor had a pattern of disease spread similar to that described in high-grade gliomas. The presumed mechanism involves disaggregation of individual tumor cells and their passive spread through the interstitial space with entry into the perivascular (Virchow-Robin) space. The perivascular sheath has been shown to be an extension of the pia and to contain fenestrations at the arteriolar level. These fenestrations may offer parenchymal tumor cells direct access to the perivascular and subarachnoid spaces. 19, 25 Neuraxis dissemination was easily identified on the initial diagnostic imaging studies in seven of our cases. In the eighth, although metastasis was not diagnosed prior to surgery, retrospective review of the initial CT scan from the referring institution revealed a metastatic tumor deposit. Although the small number of patients precludes strong comparisons of imaging modalities, MR imaging with gadolinium enhancement appears to be sensitive in detecting neuraxis dissemination. 8 Of note is the fact that neuraxis dissemination was detectable on images obtained to define the primary tumor location. Thus, especially in view of the low incidence of neuraxis dissemination, more extensive neuroimaging does not appear justified in the evaluation of patients with low-grade astrocytoma when imaging of the primary tumor does not show evidence of neuraxis dissemination.
Given the extensiveness of neuraxis dissemination in all but one of our cases, neurological symptoms were remarkably limited. In contrast, patients with histologically malignant tumors have pronounced symptoms even with tumor burdens less than noted in the current series. 22 The paucity of clinical findings in our low-grade astrocytoma patients with neuraxis dissemination may represent a diminished capacity for arachnoid invasion.
Long-term disease stabilization has followed radiation therapy in two of our cases and chemotherapy in one. The response to chemotherapy as salvage for progressive disease postirradiation has been of short duration. In general, experience with radiation therapy as salvage for young patients whose disease progresses on initial chemotherapy remains limited. Thus, the optimum treatment for these patients is yet to be determined. Our treatment approach in younger children is in accord with general trends in contemporary pediatric neurooncology in that we attempt to delay radiation therapy by the initial use of chemotherapy. 3 Treatment with carboplatin, alone or combined with vincristine, has been reported to achieve durable disease stabilization in patients with primary or recurrent lowgrade gliomas; such an approach appears warranted in a setting marked by often asymptomatic, widespread neuraxis disease in young children. 4, 13, 15 In summary, we have found neuraxis dissemination at diagnosis in 5% of children with low-grade astrocytoma. Disseminated disease is typically discernible on imaging directed to the primary tumor site. The course of disease varies from rapid progression despite chemotherapy and radiation therapy to prolonged stabilization.
